U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C16H31O2.Na
Molecular Weight 278.4059
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM PALMITATE

SMILES

[Na+].CCCCCCCCCCCCCCCC([O-])=O

InChI

InChIKey=GGXKEBACDBNFAF-UHFFFAOYSA-M
InChI=1S/C16H32O2.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18;/h2-15H2,1H3,(H,17,18);/q;+1/p-1

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C16H31O2
Molecular Weight 255.4161
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12496284 | https://www.ncbi.nlm.nih.gov/pubmed/14717706 | https://www.ncbi.nlm.nih.gov/pubmed/18511927 | https://www.ncbi.nlm.nih.gov/pubmed/23406428

Palmitic acid is a saturated fatty acid, the principal constituent of refined palm oil, present in the diet and synthesized endogenously. Palmitic acid is able to activate the orphan G protein-coupled receptor GPR40. Palmitic acid was also a weak ligand of peroxisome proliferator-activated receptor gamma. Palmitic acid is a ligand of lipid chaperones - the fatty acid-binding proteins (FABPs). Dietary palm oil and palmitic acid may play a role in the development of obesity, type 2 diabetes mellitus, cardiovascular diseases and cancer.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Palmitic acid is produced endogenously in the brain and brain penetrant in the animals.

Originator

Approval Year

1990
111
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 5.3 null [pEC50]
Binding Agent
1076
 156.0 µM [Kd]
Binding Agent
1076
Binding Agent
1076
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8583
SURFAXIN

Approved Use

SURFAXIN is indicated for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.

Launch Date

2012
PubMed

PubMed

TitleDatePubMed
Fatty acid and triglyceride composition of milk fat from lactating Holstein cows in response to supplemental canola oil.
2001 Apr
Identification of fatty acid molecules in a Fasciola hepatica immunoprophylactic fatty acid-binding protein.
2001 Apr
Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion?
2001 Apr
Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha aopototic signaling.
2001 Apr 13
Plasma membrane localization of palmitoylated tubulin.
2001 Apr 27
Myocardial fatty acid oxidation in patients with impaired glucose tolerance.
2001 Feb
Relationship between the concentrations of plasma phospholipid stearic acid and plasma lipoprotein lipids in healthy men.
2001 Jan
Characterization of a new member of the fatty acid-binding protein family that binds all-trans-retinol.
2001 Jan 12
Interaction between the unphosphorylated receptor with high affinity for IgE and Lyn kinase.
2001 Jan 12
Systemic and regional free fatty acid metabolism in type 2 diabetes.
2001 Jun
Atomic resolution structure analysis of beta' polymorph crystal of a triacylglycerol: 1,2-dipalmitoyl-3-myristoyl-sn-glycerol.
2001 Mar
Palmitoylation of the luteinizing hormone/human chorionic gonadotropin receptor regulates receptor interaction with the arrestin-mediated internalization pathway.
2001 Mar
Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs.
2001 Mar
Expression of rat liver long-chain acyl-CoA synthetase and characterization of its role in the metabolism of R-ibuprofen and other fatty acid-like xenobiotics.
2001 Mar 15
Phospholipids reacylation and palmitoylcoa control tumour necrosis factor-alpha sensitivity.
2001 Mar 7
Imaging of monolayers composed of palmitic acid and lung surfactant protein B.
2001 May
Identification and quantitation of unique fatty acid oxidation products in human atherosclerotic plaque using high-performance liquid chromatography.
2001 May 15
Patents

Patents

2682549
4
2791596
4
JP2000178208A
15
JPH06345802A
21

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
The conditioned media from palmitic acid (0.2 mM) treated rat cortical astroglia, but not the cerebellar astroglia, significantly elevated levels of phosphorylated tau and BACE1 in cortical neurons as compared to controls
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:47:54 GMT 2025
Edited
by admin
on Mon Mar 31 18:47:54 GMT 2025
Record UNII
JQ43KP6296
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
C-LUBE 16
Preferred Name English
SODIUM PALMITATE
HSDB   INCI  
INCI  
Official Name English
INS NO.470(I)PALMITIC ACID, SODIUM SALT
Common Name English
INS-470(I)PALMITIC ACID, SODIUM SALT
Common Name English
E-470(I)PALMITIC ACID, SODIUM SALT
Common Name English
SODIUM PALMITATE [HSDB]
Common Name English
HEXADECANOIC ACID, SODIUM SALT (1:1)
Common Name English
HEXADECANOIC ACID, SODIUM SALT
Common Name English
SODIUM HEXADECANOATE
Systematic Name English
PALMITIC ACID, SODIUM SALT
Common Name English
Classification Tree Code System Code
CODEX ALIMENTARIUS (GSFA) INS-470(I)
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
EPA PESTICIDE CODE 600119
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
CFR 21 CFR 186.1771
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
JECFA EVALUATION INS-470(I)
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
Code System Code Type Description
FDA UNII
JQ43KP6296
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
PRIMARY
DAILYMED
JQ43KP6296
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
PRIMARY
ECHA (EC/EINECS)
206-988-1
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
PRIMARY
EPA CompTox
DTXSID2041127
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
PRIMARY
CAS
408-35-5
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
PRIMARY
SMS_ID
300000054641
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
PRIMARY
HSDB
759
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
PRIMARY
RXCUI
1364910
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
PRIMARY RxNorm
PUBCHEM
2735111
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
PRIMARY
WIKIPEDIA
Sodium palmitate
Created by admin on Mon Mar 31 18:47:54 GMT 2025 , Edited by admin on Mon Mar 31 18:47:54 GMT 2025
PRIMARY
Related Record Type Details
Structure of PALMITIC ACID
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966